Design Therapeutics Inc
DSGN
Get informed when a big investor buys or sells
+ FollowMarket Cap$654.55M
Close$
$0.28
97.3% downside
Current Fair Value
97.3% downsideOvervalued by 97.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $654.55 Million |
|---|---|
| Enterprise Value | $644.51 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.22 |
| Beta | 1.74 |
| Outstanding Shares | 61,434,457 |
Return
| Return on Equity | -31.97% |
|---|---|
| Return on Assets | -30.25% |
| Return on Invested Capital | -38.01% |
Valuation & Multiples
| P/E Ratio | -9.24 |
|---|---|
| PEG | 2070.97 |
| Price to Sales | - |
| Price to Book Ratio | 3.48 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -7.7 |
| Enterprise Value to Net Income | -10 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.36
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 2.18% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 66.26%▼ 0.67% |
|---|---|
| Total Invested | $404.11M▲ 13.02% |
| Investors Holding | 124▲ 6.00% |
ESG Score
No data
About Design Therapeutics Inc
15 employeesDesign Therapeutics is a biotechnology company developing a new class of therapies based on a platform of gene targeted chimera (GeneTAC™) small molecules. The company’s lead program is focused on the treatment of Friedreich ataxia, foll...